Lv2
146 积分 2024-01-10 加入
Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial
2个月前
已完结
A Long-acting Glucose-dependent Insulinotropic Polypeptide Receptor Agonist Improved Insulin Sensitivity and Beta-Cell Function in Participants with Type 2 Diabetes
2个月前
已关闭
The weight-loss-independent hepatoprotective benefits of semaglutide are orchestrated by intrahepatic sinusoidal endothelial GLP-1 receptors
2个月前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
9个月前
已完结
Once-Monthly Maridebart Cafraglutide for the Treatment of Obesity — A Phase 2 Trial
9个月前
已完结
Unravelling the GIPR agonist versus antagonist paradox
10个月前
已完结
The effects of GIP, GLP-1 and GLP-2 on markers of bone turnover: a review of the gut-bone axis
10个月前
已完结
RIPK1 and necroptosis role in premature ageing
11个月前
已完结
From RIPK1 to Necroptosis: Pathogenic Mechanisms in Neurodegenerative Diseases
11个月前
已完结
RIPK1: A Promising Target for Intervention Neuroinflammation
11个月前
已完结
皖公网安备34019202002308
